Investors Net 90% Gain in GSK's $58/Share RAPT Buyout

Edgen Stock·Mar 21 2026, 23:37

Share to

Share to

Copy link

Key Takeaways

GSK completed its acquisition of RAPT Therapeutics for $58 per share, crystallizing major gains for investment firms FCPM III Services and OrbiMed Advisors. The firms had built significant positions in the biotech company in the preceding quarter at prices around $31 per share. The buyout, valued at approximately $2.2 billion, was driven by the strategic value of RAPT's late-stage food allergy drug candidate, ozureprubart.

FCPM III Services and OrbiMed Advisors collectively invested over $63 million in RAPT Therapeutics during the fourth quarter of 2025.
GSK acquired RAPT for $58 per share on March 3, 2026, representing a premium of nearly 90% on the investors' average purchase price.
The deal was centered on acquiring RAPT's promising clinical-stage drug, ozureprubart, which targets the large and underserved food allergy market.

Firms Secure 90% Premium on $63M RAPT Bet

Two investment firms, FCPM III Services and OrbiMed Advisors, made significant and well-timed purchases in RAPT Therapeutics just before its acquisition. According to SEC filings from February 17, 2026, FCPM acquired 1.5 million shares for an estimated $46.24 million in the fourth quarter of 2025, while OrbiMed purchased 556,273 shares for $17.28 million. These investments, based on an average quarterly price near $31 per share, proved prescient as the company's value was about to be redefined.

GSK Pays $2.2B for Allergy Drug Candidate

On March 3, 2026, GSK finalized its acquisition of RAPT Therapeutics for $58 per share, a deal valued at approximately $2.2 billion. This price delivered a nearly 90% premium over FCPM's estimated purchase price and a 75% gain over RAPT's closing price of $33.15 on December 31, 2025. The buyout transformed what was a fundamental biotech investment into a highly profitable, short-term event for the fourth-quarter buyers.

The acquisition's strategic driver was RAPT's late-stage asset, ozureprubart, an anti-IgE therapy for food allergies. This market represents a significant unmet medical need, affecting more than 17 million people in the United States alone. GSK's willingness to pay a substantial premium highlights the value that large pharmaceutical firms place on promising clinical-stage assets to bolster their drug pipelines, particularly in high-growth areas like immunology.

Investment Thesis Hinged on Pipeline Value

The trades demonstrate an investment strategy focused on asset conviction rather than deal speculation. FCPM and OrbiMed built their positions based on the underlying potential of RAPT's drug development pipeline, not on certainty of a takeover. For investors, this event shows how identifying clinical-stage companies with high-quality assets can lead to significant returns when a strategic buyer recognizes that same value. The rapid repricing of RAPT stock post-acquisition underscores the market's validation of its scientific platform and its lead drug candidate.